Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMWOSKJ)

Drug Name
Zolpidem Drug Info
Synonyms
zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem
Cross-matching ID
PubChem CID
5732
ChEBI ID
CHEMBL10125
CAS Number
CAS 82626-48-0
TTD Drug ID
D0T1WN
INTEDE Drug ID
DR1735
ACDINA Drug ID
D00744

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.69 0.00e+0 101/150 (67.33%) HNRNPM;LSM5;SNRPA;...
Ribosome biogenesis in eukaryotes 2.44 0.00e+0 52/108 (48.15%) NOP56;DKC1;IMP3;...
RNA transport 2.17 0.00e+0 128/186 (68.82%) TACC3;EIF3B;ELAC2;...
mRNA surveillance pathway 2.01 4.19e-3 71/98 (72.45%) NXF1;PNN;DAZAP1;...
DNA replication 1.95 5.03e-3 34/36 (94.44%) MCM5;MCM3;FEN1;...
Fatty acid biosynthesis 1.93 4.19e-3 16/18 (88.89%) FASN;ACSL1;MCAT;...
Oocyte meiosis 1.86 5.99e-3 90/129 (69.77%) CDC20;PLK1;CUL1;...
Cell cycle 1.74 2.73e-2 110/124 (88.71%) CDC20;TGFB1;PLK1;...
Dilated cardiomyopathy 1.71 2.98e-2 86/96 (89.58%) TGFB1;PLN;ITGA6;...
Regulation of lipolysis in adipocytes 1.69 3.86e-2 52/55 (94.55%) PTGER3;PLIN1;FABP4;...
Aminoacyl-tRNA biosynthesis 1.66 4.12e-2 15/66 (22.73%) FARSA;CARS2;SARS2;...
Base excision repair 1.66 3.84e-2 29/33 (87.88%) APEX1;FEN1;POLD1;...
Wnt signaling pathway 1.66 3.55e-2 124/166 (74.7%) SFRP1;MYC;FZD5;...
Progesterone-mediated oocyte maturation 1.64 4.13e-2 75/100 (75%) PLK1;RAF1;AURKA;...
Sulfur metabolism -1.70 1.76e-2 9/10 (90%) SELENBP1;TST;SQOR;...
Graft-versus-host disease -1.71 1.66e-2 32/42 (76.19%) HLA-B;HLA-G;KIR3DL1;...
Kaposi sarcoma-associated herpesvirus infection -1.72 1.56e-2 172/193 (89.12%) PPP3CC;IRF9;PIK3R1;...
Mitophagy -1.74 1.32e-2 56/68 (82.35%) TFE3;ATG5;TP53;...
Non-alcoholic fatty liver disease -1.75 1.37e-2 126/155 (81.29%) NDUFB7;CYP2E1;PIK3CA;...
Natural killer cell mediated cytotoxicity -1.75 1.42e-2 99/131 (75.57%) KIR3DL1;NRAS;PIK3CD;...
Osteoclast differentiation -1.75 1.39e-2 117/127 (92.13%) FOSL1;TNF;PPP3CC;...
Epithelial cell signaling in Helicobacter pylori infect... -1.76 1.45e-2 62/70 (88.57%) ATP6V1B1;ATP6V1B2;PLCG2;...
Butanoate metabolism -1.76 1.25e-2 23/28 (82.14%) GAD1;ALDH5A1;HMGCS1;...
Lipid and atherosclerosis -1.76 1.31e-2 190/215 (88.37%) CALML4;JAK2;EIF2AK3;...
Staphylococcus aureus infection -1.76 1.38e-2 72/95 (75.79%) C1R;DSG1;CAMP;...
Hematopoietic cell lineage -1.80 1.15e-2 90/99 (90.91%) TNF;CD14;HLA-DRB1;...
Pathogenic Escherichia coli infection -1.80 1.08e-2 152/197 (77.16%) CLDN14;IL18;RELA;...
Lysosome -1.82 1.08e-2 115/128 (89.84%) TCIRG1;CD68;ACP2;...
Phagosome -1.83 9.33e-3 118/152 (77.63%) DYNC1I2;CTSL;ATP6V1B1;...
Primary bile acid biosynthesis -1.83 9.96e-3 15/17 (88.24%) AKR1D1;CYP39A1;BAAT;...
Necroptosis -1.83 1.07e-2 113/159 (71.07%) FADD;IFNGR2;CAPN2;...
Influenza A -1.85 8.84e-3 156/172 (90.7%) TNF;CCL2;HLA-DRB1;...
Pertussis -1.88 6.70e-3 64/76 (84.21%) IL23A;ITGAM;IL6;...
Oxidative phosphorylation -1.93 4.18e-3 93/133 (69.92%) NDUFB4;NDUFS6;ATP6V0C;...
Measles -1.94 2.30e-3 133/139 (95.68%) IRF9;PIK3R1;CD46;...
Cytokine-cytokine receptor interaction -1.97 2.55e-3 246/295 (83.39%) CD40LG;CCL4;TNFRSF4;...
Synthesis and degradation of ketone bodies -2.01 1.44e-3 9/10 (90%) HMGCS1;BDH2;HMGCL;...
Legionellosis -2.06 0.00e+0 51/57 (89.47%) ITGAM;BNIP3;IL6;...
NOD-like receptor signaling pathway -2.15 0.00e+0 145/181 (80.11%) CTSB;MAPK3;IFNAR1;...
NF-kappa B signaling pathway -2.15 0.00e+0 90/104 (86.54%) ICAM1;LTB;BIRC2;...
Viral protein interaction with cytokine and cytokine re... -2.23 0.00e+0 84/100 (84%) IL10;CCL4;TNF;...
IL-17 signaling pathway -2.25 0.00e+0 84/94 (89.36%) IL17RB;MMP3;MUC5B;...
TNF signaling pathway -2.26 0.00e+0 103/112 (91.96%) EDN1;TNF;CCL2;...
Rheumatoid arthritis -2.32 0.00e+0 78/93 (83.87%) ICAM1;LTB;IL23A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 0.12uM - 10uM 24H
TC-32 CVCL_7141 Homo sapiens 0.12uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Brain
Glioblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-251 MG CVCL_0021 Homo sapiens 0.12uM - 10uM 24H
YH-13 CVCL_1800 Homo sapiens 0.12uM - 10uM 24H
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 0.12uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 0.12uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-474 CVCL_0179 Homo sapiens 0.12uM - 10uM 24H
T-47D CVCL_0553 Homo sapiens 0.12uM - 10uM 24H
ZR-75-1 CVCL_0588 Homo sapiens 0.12uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GP2d CVCL_1234 Homo sapiens 0.12uM - 10uM 24H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 0.12uM - 10uM 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WA09 (H9) Derived CVCL_9773 (WA09) Homo sapiens 0.12uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.12uM - 1.11uM 24H
HEC-151 CVCL_2927 Homo sapiens 0.12uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 0.12uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 0.12uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 0.12uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 0.12uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Renal cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RCC10RGB CVCL_1656 Homo sapiens 0.12uM - 10uM 24H
Rhabdoid tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
G-401 CVCL_0270 Homo sapiens 0.12uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 0.12uM - 10uM 24H
JHH-7 CVCL_1322 Homo sapiens 0.12uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
NCI-H1437 CVCL_1472 Homo sapiens 0.12uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 0.12uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 0.12uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 0.12uM - 10uM 24H
HCC1588 CVCL_1263 Homo sapiens 0.12uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 0.12uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 0.12uM - 10uM 24H
NCI-H2172 CVCL_1534 Homo sapiens 0.12uM - 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H841 CVCL_1595 Homo sapiens 0.12uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 0.12uM - 10uM 24H
Oral cavity
Oral squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BICR 6 CVCL_1086 Homo sapiens 0.12uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVK18 CVCL_1629 Homo sapiens 0.12uM - 10uM 24H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ES-2 CVCL_3509 Homo sapiens 0.12uM - 1.11uM 24H
OVTOKO CVCL_3114 Homo sapiens 0.12uM - 10uM 24H
Ovarian cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OAW 28 CVCL_1611 Homo sapiens 0.12uM - 10uM 24H
OC 316 CVCL_1615 Homo sapiens 0.12uM - 10uM 24H
Ovarian endometrioid carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TOV-112D CVCL_3612 Homo sapiens 0.12uM - 10uM 24H
Ovarian granulosa cell tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV434 CVCL_2010 Homo sapiens 0.12uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 0.12uM - 10uM 24H
LNCaP clone FGC CVCL_1379 Homo sapiens 0.12uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 0.12uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 0.12uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 0.12uM - 10uM 24H
SK-MEL-3 CVCL_0525 Homo sapiens 0.12uM - 10uM 24H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.12uM - 10uM 24H
MKN45 CVCL_0434 Homo sapiens 0.12uM - 10uM 24H
Gastric carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IM95 CVCL_1305 Homo sapiens 0.12uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 0.12uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 0.12uM - 10uM 24H